---
title: "HANSOH PHARMA's candidate drug HX111 has completed the first patient dosing"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/274840226.md"
description: "HANSOH PHARMA - B announced that the company has initiated a Phase I clinical trial for its self-developed candidate drug HX111 (a candidate drug targeting OX40 antibody conjugate) for relapsed refractory lymphoma and solid tumors, successfully completing the first patient enrollment and dosing recently"
datetime: "2026-02-04T15:51:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274840226.md)
  - [en](https://longbridge.com/en/news/274840226.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274840226.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/274840226.md) | [繁體中文](https://longbridge.com/zh-HK/news/274840226.md)


# HANSOH PHARMA's candidate drug HX111 has completed the first patient dosing

HANSOH PHARMA - B (03378.HK) announced that the company has initiated a Phase I clinical trial for its independently developed candidate drug HX111 (a candidate drug targeting OX40 antibody conjugate) for relapsed refractory lymphoma and solid tumors, successfully completing the first patient enrollment and dosing recently

### 相关股票

- [HANSOH PHARMA (03692.HK)](https://longbridge.com/zh-CN/quote/03692.HK.md)

## 相关资讯与研究

- [Hansoh Pharmaceutical's Application for Lung Cancer Drug Accepted in China](https://longbridge.com/zh-CN/news/277426944.md)
- [HUTCHMED to Withdraw Cancer Drug TAZVERIK in Greater China After Ipsen Safety Move](https://longbridge.com/zh-CN/news/278365432.md)
- [Hengrui Medicine Gets Nod for Chronic Kidney Disease Drug Trial](https://longbridge.com/zh-CN/news/278525391.md)
- [Fosun Pharmaceutical Unit Gets Clinical Trial Approval for Cancer Drug](https://longbridge.com/zh-CN/news/278501201.md)
- [The quiet resurgence of plant-based illicit drugs](https://longbridge.com/zh-CN/news/278733066.md)